Dr MELLITZER Georg

Fiche personne

Coordonnées

Inserm U1113
3 avenue Molière
67200 STRASBOURG

03 88 27 77 27

Territoire

Alsace

Statut

Chercheur

Affiliation

Inserm U1113 - Interface de Recherche Fondamentale et Appliquée en Cancérologie (Inserm U1113 IRFAC)

Équipes/plateformes

Equipe U1113 - Equipe "Réponse au Stress et Thérapies Innovantes (STREINTH)"

Plateforme Xénogreffes de tumeurs humaines chez la souris immunodéficiente

Publications

The unfolded protein response-glutathione metabolism axis: A novel target of a cycloruthenated complexes bypassing tumor resistance mechanisms.

Riegel G, Orvain C, Recberlik S, Spaety ME, Poschet G, Venkatasamy A, Yamamoto M, Nomura S, Tsukamoto T, Masson M, Gross I, Le Lagadec R, Mellitzer G, Gaiddon C

Cancer Lett. 2024 01 28;:216671

Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation.

Kwan K, Castro-Sandoval O, Ma B, Martelino D, Saffari A, Liu XL, Orvain C, Mellitzer G, Gaiddon C, Storr T

J Inorg Biochem. 2023 11 22;251:112433

A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.

Mourtada J, Lony C, Nicol A, De Azevedo J, Bour C, Macabre C, Roncarati P, Ledrappier S, Schultz P, Borel C, Burgy M, Wasylyk B, Mellitzer G, Herfs M, Gaiddon C, Jung AC

Front Immunol. 2023 10 25;14:1264093

Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C.

Miller JJ, Kwan K, Blanchet A, Orvain C, Mellitzer G, Smith J, Lento C, Nouchikian L, Omoregbee-Leichnitz S, Sabatou M, Wilson D, Gaiddon C, Storr T

J Inorg Biochem. 2023 02 21;242:112164

Morpho-functional analysis of patient-derived xenografts reveals differential impact of gastric cancer and chemotherapy on the tumor ecosystem, affecting immune check point, metabolism, and sarcopenia.

Venkatasamy A, Guerin E, Reichardt W, Devignot V, Chenard MP, Miguet L, Romain B, Jung AC, Gross I, Gaiddon C, Mellitzer G

Gastric Cancer. 2022 12 19;:

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?

Badie A, Gaiddon C, Mellitzer G

Cancers (Basel). 2022 11 7;14(21):

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.

De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC

Cells. 2022 09 14;11(18):

Ultrasound and Transcriptomics Identify a Differential Impact of Cisplatin and Histone Deacetylation on Tumor Structure and Microenvironment in a Patient-Derived In Vivo Model of Gastric Cancer.

Venkatasamy A, Guerin E, Blanchet A, Orvain C, Devignot V, Jung M, Jung AC, Chenard MP, Romain B, Gaiddon C, Mellitzer G

Pharmaceutics. 2021 Sep 16;13(9):

Bypassing the Resistance Mechanisms of the Tumor Ecosystem by Targeting the Endoplasmic Reticulum Stress Pathway Using Ruthenium- and Osmium-Based Organometallic Compounds: An Exciting Long-Term Collaboration with Dr. Michel Pfeffer.

Gaiddon C, Gross I, Meng X, Sidhoum M, Mellitzer G, Romain B, Delhorme JB, Venkatasamy A, Jung AC, Pfeffer M

Molecules. 2021 Sep 4;26(17):

Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair.

Blanchet A, Bourgmayer A, Kurtz JE, Mellitzer G, Gaiddon C

Cancers (Basel). 2021 Feb 22;13(4):

The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms.

Beck M, Baranger M, Moufok-Sadoun A, Bersuder E, Hinkel I, Mellitzer G, Martin E, Marisa L, Duluc I, de Reynies A, Gaiddon C, Freund JN, Gross I

Oncogene. 2020 Nov 13;:

HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.

Spaety ME, Gries A, Badie A, Venkatasamy A, Romain B, Orvain C, Yanagihara K, Okamoto K, Jung AC, Mellitzer G, Pfeffer S, Gaiddon C

Cancers (Basel). 2019 Nov 7;11(11):

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Camacho RC, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C

Cancer Lett.. 2018 Oct 16;:

A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin.

Licona C, Spaety ME, Capuozzo A, Ali M, Santamaria R, Armant O, Delalande F, Van Dorsselaer A, Cianferani S, Spencer J, Pfeffer M, Mellitzer G, Gaiddon C

Oncotarget. 2017 Jan;8(2):2568-2584